AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35711561 — intervention group
Group type: COMPARATOR
Intervention: Extensively hydrolyzed formula
Number of subjects: 190
Study 35712095 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-onset LN group
Number of subjects: 1264
Study 35712095 — intervention group
Group type: COMPARATOR
Intervention: Early-onset LN group
Number of subjects: 1264
Study 35712110 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional acupuncture (TA)
Number of subjects: 3
Study 35712110 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture (LA)
Number of subjects: 3
Study 35712110 — intervention group
Group type: COMPARATOR
Intervention: Sham laser acupuncture (SLA)
Number of subjects: 3
Study 35712111 — intervention group
Group type: EXPERIMENTAL
Intervention: PMA-zeolite supplementation (long-term, 4 years)
Number of subjects: 0
Study 35712111 — intervention group
Group type: EXPERIMENTAL
Intervention: PMA-zeolite supplementation (short-term, 28 days)
Number of subjects: 0
Study 35712111 — intervention group
Group type: EXPERIMENTAL
Intervention: PMA-zeolite supplementation (medium-term, 12 weeks)
Number of subjects: 0
Study 35712433 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement
Number of subjects: 24
Study 35712433 — intervention group
Group type: COMPARATOR
Intervention: Delayed implant placement
Number of subjects: 24
Study 35712448 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB) training using Axon EEG NFB systems, 32-48 sessions over 8 weeks
Number of subjects: 16
Study 35712448 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB) training
Number of subjects: 16
Study 35712486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab (200 mg) and Anlotinib (12 mg once daily on days 1 to 14 every 3 weeks)
Number of subjects: 20
Study 35712486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus Anlotinib
Number of subjects: 20
Study 35712797 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir (100 mg nirmatrelvir with 100 mg ritonavir)
Number of subjects: 34
Study 35712977 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent implantable collagen tile brachytherapy for brain tumors
Number of subjects: 0
Study 35713008 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating IL-6 levels
Number of subjects: 4334
Study 35713054 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-related mobile application based on artificial intelligence
Number of subjects: 0
Study 35713054 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group with pamphlet instructions
Number of subjects: 0
Study 35713149 — intervention group
Group type: EXPERIMENTAL
Intervention: Working from home
Number of subjects: 0
Study 35713149 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35713209 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly Calendar Planning Activity (WCPA)
Number of subjects: 0
Study 35713300 — intervention group
Group type: COMPARATOR
Intervention: Tixagevimab/cilgavimab
Number of subjects: 9749
Study 35713300 — intervention group
Group type: COMPARATOR
Intervention: Casirivimab/imdevimab
Number of subjects: 9749
Study 35713300 — intervention group
Group type: COMPARATOR
Intervention: Bamlanivimab
Number of subjects: 9749
Study 35713509 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral β-blocker therapy (users)
Number of subjects: 43640
Study 35713509 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose β-blocker therapy (metoprolol-equivalent dose ≥50 mg/day)
Number of subjects: 43640
Study 35713509 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose β-blocker therapy (metoprolol-equivalent dose <50 mg/day)
Number of subjects: 43640
Study 35713509 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol vs. Bisoprolol
Number of subjects: 43640
Study 35713539 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 lockdown
Number of subjects: 0
Study 35713551 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 0
Study 35713599 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher frequency of mantram repetition practice
Number of subjects: 0
Study 35713720 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous TeleHealth care (web-based questionnaire)
Number of subjects: 33
Study 35713720 — intervention group
Group type: COMPARATOR
Intervention: In-person visits
Number of subjects: 33
Study 35713873 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 372
Study 35713929 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE treatment
Number of subjects: 0
Study 35713944 — intervention group
Group type: EXPERIMENTAL
Intervention: forDiabetes mobile app
Number of subjects: 0
Study 35713944 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 35714051 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher number of stressful life events (2010-11)
Number of subjects: 224
Study 35714051 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group with optimal LDL cholesterol and triglyceride levels)
Number of subjects: 224
Study 35714099 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Care Program (DCP) for MSK pain
Number of subjects: 7785
Study 35714311 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs) - 17 ledipasvir/sofosbuvir, 8 sofosbuvir plus ribavirin, 15 sofosbuvir/velpatasvir
Number of subjects: 40
Study 35714311 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs)
Number of subjects: 40
Study 35714349 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Replacement
Number of subjects: 0
Study 35714426 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning mentoring education containing a cultural competence component (Intervention group)
Number of subjects: 111
Study 35714426 — intervention group
Group type: COMPARATOR
Intervention: Online mentoring education lacking a cultural competence component (Control group)
Number of subjects: 111
Study 35714431 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged dual antiplatelet therapy (DAPT) for 12-24 months
Number of subjects: 0
Study 35714431 — intervention group
Group type: COMPARATOR
Intervention: Standard dual antiplatelet therapy (DAPT) for 6-12 months
Number of subjects: 0
Study 35714445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 22120
Study 35714649 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive diagnostic procedures for encephalitis
Number of subjects: 664
Study 35714649 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis virus
Number of subjects: 664
Study 35714649 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue virus
Number of subjects: 664
Study 35714649 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza virus
Number of subjects: 664
Study 35714649 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes simplex virus 1
Number of subjects: 664
Study 35714649 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium tuberculosis
Number of subjects: 664
Study 35714649 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptococcus pneumoniae
Number of subjects: 664
Study 35714649 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterovirus A71
Number of subjects: 664
Study 35714649 — intervention group
Group type: EXPERIMENTAL
Intervention: Other pathogens
Number of subjects: 664
Study 35714649 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoimmune encephalitis
Number of subjects: 664
Study 35714649 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe neurological sequelae
Number of subjects: 664
Study 35714649 — intervention group
Group type: EXPERIMENTAL
Intervention: Death
Number of subjects: 664
Study 35714649 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for unfavourable outcomes
Number of subjects: 664
Study 35714649 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 1 year after inclusion
Number of subjects: 664
Study 35714666 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided focused ultrasound focal therapy
Number of subjects: 101
Study 35714735 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV2-hCHM subretinal injections
Number of subjects: 15
Study 35715176 — intervention group
Group type: EXPERIMENTAL
Intervention: Public and Patient Engagement Evaluation Tool (PPEET) questionnaire
Number of subjects: 0
Study 35715176 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews
Number of subjects: 0
Study 35715340 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with a median dose of 36.25 Gy in five fractions
Number of subjects: 24
Study 35715340 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 24
Study 35715405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralsetinib
Number of subjects: 0
Study 35715405 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab monotherapy
Number of subjects: 0
Study 35715405 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab with chemotherapy
Number of subjects: 0
Study 35715492 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol awakening response in EPT children
Number of subjects: 139
Study 35715492 — intervention group
Group type: COMPARATOR
Intervention: Cortisol awakening response in term-born children
Number of subjects: 139
Study 35715566 — intervention group
Group type: EXPERIMENTAL
Intervention: Onasemnogene abeparvovec
Number of subjects: 14
Study 35715567 — intervention group
Group type: EXPERIMENTAL
Intervention: Onasemnogene abeparvovec
Number of subjects: 15
Study 35715627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobimetinib (tablet) at a recommended Phase II dose (RP2D) of 0.8 mg/kg
Number of subjects: 56
Study 35715627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobimetinib (suspension) at a recommended Phase II dose (RP2D) of 1.0 mg/kg
Number of subjects: 56
Study 35715627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobimetinib (tablet and suspension)
Number of subjects: 56
Study 35715627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Number of subjects: 56
Study 35715631 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity classification (≦0.33 MET-h/wk, 0.34-16.65 MET-h/wk, ≥16.6 MET-h/wk)
Number of subjects: 1075
Study 35715631 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity dose classification
Number of subjects: 1075
Study 35715801 — intervention group
Group type: EXPERIMENTAL
Intervention: Seraph® 100 Microbind® Affinity Blood Filter treatment
Number of subjects: 15
Study 35715823 — intervention group
Group type: EXPERIMENTAL
Intervention: Model trained on stroke data
Number of subjects: 20
Study 35715823 — intervention group
Group type: COMPARATOR
Intervention: Model trained on control data
Number of subjects: 20
Study 35715980 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal egg intake
Number of subjects: 0
Study 35715980 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline and L/Z intake interaction
Number of subjects: 0
Study 35715980 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline, L/Z, and DHA interaction
Number of subjects: 0
Study 35715980 — intervention group
Group type: EXPERIMENTAL
Intervention: L/Z intake
Number of subjects: 0
Study 35715980 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline and L/Z interaction
Number of subjects: 0
Study 35715980 — intervention group
Group type: EXPERIMENTAL
Intervention: L/Z and DHA interaction
Number of subjects: 0
Study 35716238 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Diabetes Routines Questionnaire for Parents of Young Children (PDRQ-PYC)
Number of subjects: 173
Study 35716331 — intervention group
Group type: EXPERIMENTAL
Intervention: High broad-spectrum sunscreen medical device (MD) containing UVB and UVA filters and 1% ectoin, applied at a dosage of 2 mg/cm².
Number of subjects: 13
Study 35716331 — intervention group
Group type: COMPARATOR
Intervention: Untreated control side (no sunscreen applied).
Number of subjects: 13
Study 35716331 — intervention group
Group type: EXPERIMENTAL
Intervention: High broad-spectrum sunscreen medical device (MD).
Number of subjects: 13
Study 35716332 — intervention group
Group type: EXPERIMENTAL
Intervention: Difamilast 1% ointment (adults)
Number of subjects: 366
Study 35716332 — intervention group
Group type: EXPERIMENTAL
Intervention: Difamilast 0.3% ointment (pediatrics)
Number of subjects: 366
Study 35716332 — intervention group
Group type: EXPERIMENTAL
Intervention: Difamilast 1% ointment (pediatrics)
Number of subjects: 366
Study 35716543 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP adherence (≥4 hours for ≥70% of nights over 3 months)
Number of subjects: 52
Study 35716543 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline demographic and stroke-related factors
Number of subjects: 52
Study 35716543 — intervention group
Group type: COMPARATOR
Intervention: Early CPAP complaints
Number of subjects: 52
Study 35716543 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators of adherence
Number of subjects: 52
Study 35716543 — intervention group
Group type: COMPARATOR
Intervention: Barriers to adherence
Number of subjects: 52
Study 35716700 — intervention group
Group type: EXPERIMENTAL
Intervention: BioFire Global Fever Panel (GF Panel)
Number of subjects: 1965
Study 35716871 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal graft (Xenform)
Number of subjects: 713
Study 35716871 — intervention group
Group type: COMPARATOR
Intervention: Native tissue repair
Number of subjects: 713
Study 35717027 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine (30 mg/m²) in combination with pembrolizumab
Number of subjects: 34
Study 35717147 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG polysomnography and sleep actigraphy in infants with AD
Number of subjects: 50
Study 35717147 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized severity assessment tools for AD
Number of subjects: 50
Study 35717147 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental assessment at 18 months
Number of subjects: 50
Study 35717147 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly questionnaires on sleep and parental sleep
Number of subjects: 50
Study 35717147 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin barrier and immune profiles at six-eight and 12 months
Number of subjects: 50
Study 35717179 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher degree of pain severity
Number of subjects: 1127
Study 35717179 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher degree of disability
Number of subjects: 1127
Study 35717179 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher degree of depression
Number of subjects: 1127
Study 35717179 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower degree of physical health-related quality of life
Number of subjects: 1127
Study 35717179 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiophobia
Number of subjects: 1127
Study 35717179 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery expectations
Number of subjects: 1127
Study 35717179 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity
Number of subjects: 1127
Study 35717179 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiating pain below the knee
Number of subjects: 1127
Study 35717179 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health-related quality of life
Number of subjects: 1127
Study 35717182 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcerative OLP
Number of subjects: 52
Study 35717182 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythematous OLP
Number of subjects: 52
Study 35717182 — intervention group
Group type: EXPERIMENTAL
Intervention: Reticular OLP
Number of subjects: 52
Study 35717182 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 35717381 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic patients
Number of subjects: 5609
Study 35717381 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic gene carriers
Number of subjects: 5609
Study 35717608 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance (IR)
Number of subjects: 729
Study 35717608 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-cell dysfunction (BCD)
Number of subjects: 729
Study 35717608 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance (IR) and beta-cell dysfunction (BCD)
Number of subjects: 729
Study 35717608 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analyses
Number of subjects: 729
Study 35717635 — intervention group
Group type: COMPARATOR
Intervention: No hygiene recommendations (part 1)
Number of subjects: 9661
Study 35717635 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin pregnancy
Number of subjects: 9661
Study 35717635 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal medical conditions
Number of subjects: 9661
Study 35718119 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based smoking cessation intervention
Number of subjects: 439
Study 35718763 — intervention group
Group type: EXPERIMENTAL
Intervention: NoMAD (Normalization Measurement Development questionnaire)
Number of subjects: 56
Study 35718763 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual traffic light summary (TLS)
Number of subjects: 56
Study 35718782 — intervention group
Group type: EXPERIMENTAL
Intervention: PD + Teacher-Wellness (PDT)
Number of subjects: 540
Study 35718782 — intervention group
Group type: EXPERIMENTAL
Intervention: PD alone (PD)
Number of subjects: 540
Study 35718782 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 540
Study 35718845 — intervention group
Group type: EXPERIMENTAL
Intervention: HCMSQ (Hypertrophic Cardiomyopathy Symptom Questionnaire)
Number of subjects: 0
Study 35718845 — intervention group
Group type: EXPERIMENTAL
Intervention: HCMSQ
Number of subjects: 0
Study 35719001 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute dosing interval
Number of subjects: 0
Study 35719001 — intervention group
Group type: COMPARATOR
Intervention: 30-minute dosing interval
Number of subjects: 0
Study 35719139 — intervention group
Group type: EXPERIMENTAL
Intervention: BOSB (bean and oats snack bar), 50 g per day
Number of subjects: 26
Study 35719139 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 35719155 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate malnutrition diagnosed in patients with chronic pancreatitis (CP)
Number of subjects: 66
Study 35719155 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 66
Study 35719690 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study 35719690 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35719960 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (100mg/m) + phenelzine (60mg daily)
Number of subjects: 0
Study 35720061 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-to-left shunt (RLS) in patients with benign recurrent vertigo (BRV)
Number of subjects: 2751
Study 35720061 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-to-left shunt (RLS) in patients with vestibular migraine (VM)
Number of subjects: 2751
Study 35720061 — intervention group
Group type: COMPARATOR
Intervention: Control group (benign paroxysmal positional vertigo, Meniere's disease, vestibular paroxysmia)
Number of subjects: 2751
Study 35720069 — intervention group
Group type: EXPERIMENTAL
Intervention: SIOP Ependymoma II trial intervention
Number of subjects: 0
Study 35720069 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized pathology and imaging for diagnosis confirmation
Number of subjects: 0
Study 35720069 — intervention group
Group type: EXPERIMENTAL
Intervention: Central neurosurgical and radiological postoperative MRI reviews
Number of subjects: 0
Study 35720069 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational study for patients ineligible for interventional strata
Number of subjects: 0
Study 35720096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT)
Number of subjects: 14
Study 35720286 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-thrombolytic dose of tPA along with ozanimod
Number of subjects: 0
Study 35720286 — intervention group
Group type: COMPARATOR
Intervention: Sub-thrombolytic dose of tPA along with vehicle control
Number of subjects: 0
Study 35720286 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod
Number of subjects: 0
Study 35720312 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus sequential neoadjuvant chemotherapy
Number of subjects: 80
Study 35720454 — intervention group
Group type: EXPERIMENTAL
Intervention: Telestroke consultations via telemedicine
Number of subjects: 443
Study 35720675 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartwatch-smartphone app dyad for 14 days
Number of subjects: 90
Study 35720727 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mediterranean Ketogenic (MMK) diet
Number of subjects: 20
Study 35720727 — intervention group
Group type: COMPARATOR
Intervention: American Heart Association (AHA) diet
Number of subjects: 20
Study 35720980 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 600
Study 35720980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 35721046 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal Cyclosporine A for inhalation (L-CsA-i)
Number of subjects: 130
Study 35721046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 35721084 — intervention group
Group type: EXPERIMENTAL
Intervention: Camouflage combined with psychotherapy
Number of subjects: 149
Study 35721084 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 149
Study 35721350 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback for emotion regulation
Number of subjects: 0
Study 35721744 — intervention group
Group type: EXPERIMENTAL
Intervention: RJX (1.25 mL/kg or 2.5 mL/kg)
Number of subjects: 0
Study 35721744 — intervention group
Group type: COMPARATOR
Intervention: NS (control group)
Number of subjects: 0
Study 35721744 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic control rats
Number of subjects: 0
Study 35722047 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week structured physical activity programme during chemotherapy
Number of subjects: 20